Correct Answer: C. Age > 10 years
In acute lymphoblastic leukemia (ALL), age is a critical prognostic factor, and age > 10 years is associated with poor prognosis. The standard risk stratification in pediatric ALL divides patients into favorable-risk and high-risk groups based on age at diagnosis. Children aged 1–9 years (particularly 2–5 years) have the most favorable outcomes, with 5-year event-free survival (EFS) rates exceeding 85–90% in developed countries and 60–70% in Indian cohorts. Conversely, infants (< 1 year) and children > 10 years have significantly worse prognosis, with EFS rates dropping to 40–60%. The biologic basis for age-related prognostic differences includes: (1) older children have a higher frequency of unfavorable cytogenetic abnormalities (e.g., t(9;22), complex karyotype, low hyperdiploidy); (2) increased incidence of T-cell ALL, which carries worse prognosis than B-cell ALL; (3) higher leukemic burden at presentation; and (4) reduced chemotherapy tolerance and compliance in adolescents. Indian pediatric oncology guidelines (AIIMS, TATA Memorial protocols) and international COG/UKALL risk stratification systems uniformly classify age > 10 years as a high-risk feature requiring intensified therapy. This is a fundamental concept tested repeatedly in NEET PG pediatric hematology.
Why the other options are wrong
A. Leukocyte count < 50,000/mm3 — This is wrong because low leukocyte count at diagnosis is actually favorable, not poor prognosis. Standard risk stratification uses WBC count as a favorable marker when < 50,000/mm³. High WBC (> 100,000/mm³) indicates high disease burden and poor prognosis. The trap here is reversing the WBC threshold—students may confuse 'lower is better' with 'lower is worse' in hematologic malignancies. B. Hyperdiploidy — This is wrong because hyperdiploidy (especially trisomy of chromosomes 4, 10, 17) is a favorable prognostic marker. Hyperdiploidy with DNA index > 1.16 is associated with excellent prognosis (EFS > 85%) and is classified as standard-risk or low-risk in most protocols. The NBE trap conflates 'abnormal karyotype' with 'poor prognosis'—students may assume any chromosomal abnormality is bad, missing that specific hyperdiploidy patterns are protective. D. Trisomy of chromosomes 4, 10, and 17 — This is wrong because trisomy of chromosomes 4, 10, and 17 is one of the most favorable cytogenetic findings in ALL. This pattern is part of 'good hyperdiploidy' and is associated with 5-year EFS > 85–90%. It is a hallmark of standard-risk ALL. The trap is presenting a favorable cytogenetic marker as if it were unfavorable, testing whether students know specific chromosome trisomies.
High-Yield Facts
- Age 1–9 years (especially 2–5 years) = most favorable prognosis in ALL; age > 10 years = poor prognosis.
- WBC < 50,000/mm³ = favorable; WBC > 100,000/mm³ = high-risk disease with poor prognosis.
- Hyperdiploidy (DNA index > 1.16) and trisomy of chromosomes 4, 10, 17 = excellent prognosis (EFS > 85%).
- Unfavorable cytogenetics: t(9;22) Philadelphia chromosome, t(4;11), complex karyotype, hypodiploidy—all associated with poor prognosis.
- T-cell ALL carries worse prognosis than B-cell ALL; more common in older children and adolescents.
- Indian ALL 5-year EFS: ~70% (vs. 90% in developed countries); age > 10 years further reduces EFS to 40–50%.
Mnemonics
ALL Prognosis: AGE & BURDEN Age 1–9 = good | Good cytogenetics (hyperdiploidy, trisomy 4,10,17) = good | Early response to therapy = good. Bad age (< 1 or > 10) = poor | Unfavorable cytogenetics (t(9;22), complex) = poor | Raised WBC (> 100K) = poor | Delayed response = poor | Early CNS involvement = poor | Non-B, non-T (rare) = poor. Favorable vs. Unfavorable Age in ALL SWEET SPOT = 2–5 years (best prognosis). DANGER ZONES = < 1 year (infant ALL) and > 10 years (adolescent ALL). Remember: 'Goldilocks zone' for ALL is early childhood, not infancy or adolescence.
NBE Trap
NBE pairs 'age' with 'poor prognosis' to test whether students know that age > 10 years (not < 10 years) is unfavorable. The distractor options (low WBC, hyperdiploidy, specific trisomies) are all actually favorable markers, designed to trap students who confuse 'abnormality' with 'poor outcome' or who reverse the direction of WBC thresholds.
Clinical Pearl
In Indian pediatric oncology centers, adolescents (> 10 years) with ALL present with higher disease burden, more T-cell phenotype, and worse chemotherapy tolerance, requiring intensified protocols (like adolescent-adapted regimens) to improve outcomes. Age-based risk stratification is the first step in treatment planning at AIIMS and TATA Memorial.
_Reference: OP Ghai Pediatrics Ch. 12 (Hematologic Malignancies); Harrison Ch. 110 (Acute Leukemias); COG/UKALL Risk Stratification Protocols_